NC Biotech2d
Beam Therapeutics reports gene editing breakthrough
The field of gene editing recently got a major boost from Massachusetts-based Beam Therapeutics, and the company’s Durham ...
Dealbreaker on MSN17d
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough Market
A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...
Benzinga.com20d
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
BEAM-302 showed durable, dose-dependent correction of AATD mutation in 9 patients with effects seen as early as Day 7. Beam plans further dose escalation and will report new trial data in H2 2025 ...
GEN - Genetic Engineering and Biotechnology News18d
In Vivo Base Editing Gets Boost with Positive Initial Data Announced by Beam Therapeutics
Beam Therapeutics announced positive initial data for BEAM-302 in the Phase I/II trial in Alpha-1 Antitrypsin Deficiency (AATD).